Search details
1.
Predictors of Success of Phase II Pediatric Oncology Clinical Trials.
Oncologist
; 24(8): e765-e774, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30808815
2.
Correction to: International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.
J Neurooncol
; 141(2): 265, 2019 Jan.
Article
in English
| MEDLINE | ID: mdl-30484110
3.
International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.
J Neurooncol
; 141(2): 253-263, 2019 Jan.
Article
in English
| MEDLINE | ID: mdl-30446898
4.
Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia.
Semin Cell Dev Biol
; 54: 68-81, 2016 06.
Article
in English
| MEDLINE | ID: mdl-26529279
5.
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
Br J Cancer
; 119(6): 693-696, 2018 09.
Article
in English
| MEDLINE | ID: mdl-30220707
6.
Development of Orthotopic Patient-Derived Xenograft Models of Pediatric Intracranial Tumors.
Methods Mol Biol
; 2806: 75-90, 2024.
Article
in English
| MEDLINE | ID: mdl-38676797
7.
Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.
Neurooncol Adv
; 6(1): vdae029, 2024.
Article
in English
| MEDLINE | ID: mdl-38550394
8.
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
J Clin Invest
; 134(6)2024 Feb 06.
Article
in English
| MEDLINE | ID: mdl-38319732
9.
Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor.
Mol Cell Proteomics
; 10(9): M900538MCP200, 2011 Sep.
Article
in English
| MEDLINE | ID: mdl-20167946
10.
From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer.
Adv Drug Deliv Rev
; 196: 114777, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36931346
11.
Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
Mol Cancer Ther
; 22(12): 1413-1421, 2023 Dec 01.
Article
in English
| MEDLINE | ID: mdl-37683275
12.
In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma.
Front Oncol
; 13: 1123492, 2023.
Article
in English
| MEDLINE | ID: mdl-36937401
13.
From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients.
Biomedicines
; 11(11)2023 Oct 27.
Article
in English
| MEDLINE | ID: mdl-38001908
14.
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.
Cancer Res
; 83(16): 2716-2732, 2023 08 15.
Article
in English
| MEDLINE | ID: mdl-37523146
15.
Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-ß signaling pathways in cancer.
Cell Biosci
; 13(1): 132, 2023 Jul 21.
Article
in English
| MEDLINE | ID: mdl-37480151
16.
Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.
Cancer Cell
; 41(4): 660-677.e7, 2023 04 10.
Article
in English
| MEDLINE | ID: mdl-37001527
17.
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.
Theranostics
; 12(10): 4734-4752, 2022.
Article
in English
| MEDLINE | ID: mdl-35832071
18.
In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.
EMBO Mol Med
; 14(4): e14608, 2022 04 07.
Article
in English
| MEDLINE | ID: mdl-34927798
19.
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.
Cancer Res
; 82(17): 2980-3001, 2022 09 02.
Article
in English
| MEDLINE | ID: mdl-35802025
20.
Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.
Cancers (Basel)
; 13(24)2021 Dec 13.
Article
in English
| MEDLINE | ID: mdl-34944870